183 related articles for article (PubMed ID: 19586325)
21. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
Mehra M; Wu Y; Dhawan R
J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
[TBL] [Abstract][Full Text] [Related]
22. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
[TBL] [Abstract][Full Text] [Related]
23. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
24. Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.
Castellano D; Duh MS; Korves C; Suthoff ED; Neary M; Hernández Pastor LJ; Bellmunt J
Expert Opin Drug Saf; 2013 Jul; 12(4):455-63. PubMed ID: 23510293
[TBL] [Abstract][Full Text] [Related]
25. Cost of care for new versus recurrent acute coronary syndrome patients.
Shetty S; Halpern R; McCollam PL
J Med Econ; 2008; 11(1):81-99. PubMed ID: 19450112
[TBL] [Abstract][Full Text] [Related]
26. [Antiangiogenic treatment and kidney cancer: ongoing trials and future perspectives].
Oudard S; Cornu JN; Rouprêt M; Patard JJ
Prog Urol; 2008 Jul; 18 Suppl 4():S77-80. PubMed ID: 18706375
[TBL] [Abstract][Full Text] [Related]
27. A study on the economic impact of bariatric surgery.
Cremieux PY; Buchwald H; Shikora SA; Ghosh A; Yang HE; Buessing M
Am J Manag Care; 2008 Sep; 14(9):589-96. PubMed ID: 18778174
[TBL] [Abstract][Full Text] [Related]
28. Novel therapeutics for metastatic renal cell carcinoma.
Hutson TE; Figlin RA
Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
[TBL] [Abstract][Full Text] [Related]
30. The impact of psoriasis on health care costs and patient work loss.
Fowler JF; Duh MS; Rovba L; Buteau S; Pinheiro L; Lobo F; Sung J; Doyle JJ; Swensen A; Mallett DA; Kosicki G
J Am Acad Dermatol; 2008 Nov; 59(5):772-80. PubMed ID: 19119095
[TBL] [Abstract][Full Text] [Related]
31. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
[TBL] [Abstract][Full Text] [Related]
32. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck.
Lang K; Sussman M; Friedman M; Su J; Kan HJ; Mauro D; Tafesse E; Menzin J
Arch Otolaryngol Head Neck Surg; 2009 Jun; 135(6):582-8. PubMed ID: 19528407
[TBL] [Abstract][Full Text] [Related]
33. Clinical and economic consequences of antibiotic-impregnated cerebrospinal fluid shunt catheters.
Eymann R; Chehab S; Strowitzki M; Steudel WI; Kiefer M
J Neurosurg Pediatr; 2008 Jun; 1(6):444-50. PubMed ID: 18518694
[TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review.
Boehm S; Rothermundt C; Hess D; Joerger M
Gerontology; 2010; 56(3):303-9. PubMed ID: 19940466
[TBL] [Abstract][Full Text] [Related]
35. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.
Joyce AT; Smith P; Khandker R; Melin JM; Singh A
J Rheumatol; 2009 Apr; 36(4):743-52. PubMed ID: 19228658
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
37. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
[TBL] [Abstract][Full Text] [Related]
38. Identification of patients receiving peritoneal dialysis using health insurance claims data.
Berger A; Edelsberg J; Inglese G; Bhattacharyya S; Oster G
Clin Ther; 2009 Jun; 31(6):1321-34. PubMed ID: 19695397
[TBL] [Abstract][Full Text] [Related]
39. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.
Bhandari S; Naudeer S
J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894
[TBL] [Abstract][Full Text] [Related]
40. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
